Tumor Volume As a Predictor of Adverse Pathologic Features and Biochemical Recurrence (BCR) in Radical Prostatectomy Specimens: a Tale of Two Methods

Overview

Journal World J Urol

Specialty Urology

Date 2010 Nov 17

PMID 21079968

Citations 6

Authors

Ian M Thompson 3rd

Shady Salem

Sam S Chang

Peter E Clark

Rodney Davis

S Duke Herrell

Yakup Kordan

Roxelyn Baumgartner

Sharon Phillips

Joseph A Smith Jr

Michael S Cookson

Daniel A Barocas

Affiliations

Soon will be listed here.

Abstract

Purpose: The prognostic value of tumor volume in predicting biochemical recurrence after prostatectomy has been debated. Our aim in this study was to (a) evaluate tumor volume as an independent predictor of adverse pathologic outcomes and BCR and (b) determine the effect of two different methods of tumor volume estimation.

Methods: We reviewed the charts of 3,087 patients who underwent radical prostatectomy at Vanderbilt University Medical Center between 2000 and 2008; of which 1,747 patients had data sufficient for analysis. Prostate specimens were processed as whole mount between 2000 and 2003 and then via systematic sampling from 2003 to 2008, with tumor volume measured by planimetry in the whole-mount group and tumor volume estimated by percent tumor involvement in the systematic sampling group.

Results: Tumor volume estimates were higher with SS than with WM. There were significant associations between larger tumor volume and adverse pathological outcomes, regardless of pathologic method (all with P<0.001). Controlling for other pathologic parameters, tumor volume was an independent predictor of PGS, EPE, and SM in logistic regression models (P<0.001 for TV in all models). Tumor volume was demonstrated to be an independent predictor of BCR in the WM group (1.06, 95% CI 1.01-1.11, P=0.013), though tumor volume was not a significant predictor of BCR in the SS group.

Conclusions: Though the prognostic value of tumor volume is debated, our data demonstrate that tumor volume, when calculated via planimetry on whole-mount pathologic sectioning, is a significant predictor of biochemical recurrence after prostatectomy.

Citing Articles

MRI-derived tumor volume as a predictor of biochemical recurrence and adverse pathology in patients after radical prostatectomy: a propensity score matching study.

Zhu X, Liu Z, He J, Li Z, He W, Lu J J Cancer Res Clin Oncol. 2023; 149(11):8853-8861.

PMID: 37148292 DOI: 10.1007/s00432-023-04825-9.

Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer.

Baba H, Sakamoto S, Zhao X, Yamada Y, Rii J, Fujimoto A Cancers (Basel). 2022; 14(23).

PMID: 36497304 PMC: 9740872. DOI: 10.3390/cancers14235823.

Can Tumour Volume Percentage in Radical Prostatectomy Predict Cancer Biochemical Recurrence? Determining a Cut-off Point and Composite Risk Factors Approach.

Alenezi A, Ismail M, Eden C Res Rep Urol. 2021; 13:445-455.

PMID: 34235101 PMC: 8254606. DOI: 10.2147/RRU.S313455.

Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.

Choi S, Chi B, Lim B, Kyung Y, You D, Jeong I J Cancer Res Clin Oncol. 2020; 146(2):537-543.

PMID: 31915914 DOI: 10.1007/s00432-019-03085-w.

Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis.

Meng Y, Li H, Xu P, Wang J Int J Clin Exp Med. 2016; 8(12):22319-27.

PMID: 26885209 PMC: 4729995.

References

Jack G, Cookson M, Coffey C, Vader V, Roberts R, Chang S . Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. J Urol. 2002; 168(2):519-24. View

Nelson B, Shappell S, Chang S, Wells N, Farnham S, Smith Jr J . Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006; 97(6):1169-72. DOI: 10.1111/j.1464-410X.2006.06148.x. View

Merrill M, Lane B, Reuther A, Zhou M, Magi-Galluzzi C, Klein E . Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology. 2007; 70(2):294-8. DOI: 10.1016/j.urology.2007.03.062. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Salomon L, Levrel O, Anastasiadis A, Irani J, De La Taille A, Saint F . Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol. 2003; 43(1):39-44. DOI: 10.1016/s0302-2838(02)00493-1. View

Stamey T, McNeal J, Yemoto C, Sigal B, Johnstone I . Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999; 281(15):1395-400. DOI: 10.1001/jama.281.15.1395. View

Srigley J . Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med. 2006; 130(3):303-17. DOI: 10.5858/2006-130-303-KIIHAR. View

Kattan M, Wheeler T, Scardino P . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17(5):1499-507. DOI: 10.1200/JCO.1999.17.5.1499. View

Cookson M, Aus G, Burnett A, Canby-Hagino E, DAmico A, Dmochowski R . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in.... J Urol. 2007; 177(2):540-5. DOI: 10.1016/j.juro.2006.10.097. View

10.

Roehl K, Han M, Ramos C, Antenor J, Catalona W . Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172(3):910-4. DOI: 10.1097/01.ju.0000134888.22332.bb. View

11.

Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson S, Bratell S . Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352(19):1977-84. DOI: 10.1056/NEJMoa043739. View

12.

Epstein J, Carmichael M, Partin A, Walsh P . Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1993; 149(6):1478-81. DOI: 10.1016/s0022-5347(17)36421-2. View

13.

Sherwin J, Mirmilstein G, Pedersen J, Lawrentschuk N, Bolton D, Mills J . Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors. J Urol. 2010; 183(5):1808-14. DOI: 10.1016/j.juro.2010.01.017. View

14.

Kikuchi E, Scardino P, Wheeler T, Slawin K, Ohori M . Is tumor volume an independent prognostic factor in clinically localized prostate cancer?. J Urol. 2004; 172(2):508-11. DOI: 10.1097/01.ju.0000130481.04082.1a. View

15.

Zhou J, Schmid T, Schnitzer S, Brune B . Tumor hypoxia and cancer progression. Cancer Lett. 2005; 237(1):10-21. DOI: 10.1016/j.canlet.2005.05.028. View

16.

Uhlman M, Sun L, Stackhouse D, Polascik T, Mouraviev V, Robertson C . Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol. 2010; 183(3):997-1001. DOI: 10.1016/j.juro.2009.11.046. View

17.

Porter C, Kodama K, Gibbons R, Correa Jr R, Chun F, Perrotte P . 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol. 2006; 176(2):569-74. DOI: 10.1016/j.juro.2006.03.094. View

18.

Porten S, Cooperberg M, Carroll P . The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2009; 105(4):472-5. PMC: 2821458. DOI: 10.1111/j.1464-410X.2009.08774.x. View

19.

Rampersaud E, Sun L, Moul J, Madden J, Freedland S . Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol. 2008; 180(2):571-6. DOI: 10.1016/j.juro.2008.04.017. View

20.

Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L . Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366(9485):572-8. DOI: 10.1016/S0140-6736(05)67101-2. View